ASCO

Immutep revealed positive final data from Part C of the TACTI-002 Phase II trial at the ASCO 2023 Annual Meeting in Chicago, US. The trial evaluated eftilagimod alpha (efti), a soluble LAG-3 protein and first-in-class MHC Class II agonist, in combination with MSD’s (Merck) anti-PD-1 therapy Keytruda (pembrolizumab) in second line head and neck squamous cell […]

RemeGen announced the latest clinical research results on disitamab vedotin (RC48) at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. Researchers tested disitamab vedotin and toripalimab in combination on patients diagnosed with locally advanced or metastatic urothelial carcinoma (la/mUC). The objective of the study was to determine the safety and efficacy of this […]

Ground-breaking data from several key cancer trials were announced at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. ADAURA Phase III trial The trial assessed Tagrisso (osimertinib) as an adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after complete tumour […]

Positive primary endpoint data from Novartis’ pivotal Phase III NATALEE trial has been presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. Data showed that Kisqali (ribociclib) plus endocrine therapy (ET), compared to ET alone, lowered the risk of cancer recurrence by 25.2% in patients with stage II and III hormone receptor-positive/human […]

Janssen has presented new data from across its oncology pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Talquetamab Talquetamab is an investigational GPRC5D-directed bispecific antibody currently in clinical development. Updated results from the Phase II MonumenTAL-1 study show that with a median of 13-19 months of follow-up, talquetamab continues to […]

A targeted drug combination for patients with a type of ovarian cancer could be nearly twice as effective as the next best treatment, according to interim results from a Phase II study. Researchers hope these results, which were presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, will lead to a new […]

Positive results from the ADAURA Phase III trial showed AstraZeneca’s Tagrisso (osimertinib) demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared to placebo. The trial assessed osimertinib as an adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after complete […]

Biopharmaceutical company Syros Pharmaceuticals has announced new clinical data from the Phase I/Ib clinical trial evaluating SY-5609 in patients with relapsed/refractory pancreatic ductal adenocarcinoma (PDAC), HR+ breast cancer and other solid tumours. The data will be presented in two posters at the 2023 American Society for Clinical Oncology (ASCO) Annual Meeting, taking place June 2-6, […]

The upcoming 2021 American Society of Clinical Oncology (ASCO) Annual Meeting will be a digital event from June 4-8, featuring 48 educational and scientific sessions and showcasing what is possible when the cancer care community comes together to advance cancer research, treatment, and patient care. The event will allow real-time engagement, a live Q&A, and […]